This content is from: United States

Nonversion: AbbVie – Shire deal falls through but inversions will continue

The impact of a US Treasury Notice to reduce the benefits of tax inversion deals is taking effect. AbbVie has scrapped its proposed $54 billion takeover of Shire, and Salix and Cosmo have decided not to combine either.

To access our market-driven intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an ITR subscriber? Log in here

Instant access to all of our content. Membership Options | 30 Day Trial